SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities Lawsuit

ARS Pharmaceuticals is facing a securities class-action allegation that it misrepresented the timing of expanded CVS Caremark coverage for its neffy allergy treatment. The disclosure was followed by a 23.9% one-day decline in ARS shares, creating material litigation and investor-confidence risk for the company.